Neoantigen cancer vaccineVariable epitope libraryImmune escapeIn this communication, we will analyze some important factors and immunological phenomena related to neoantigen cancer vaccines, with particular emphasis on recently published Phase I clinical trials. Several obstacles and issues are addressed that ...
While the first neoantigen-based cancer vaccine clinical trials focused on ex vivo-pulsed dendritic cells, synthetic long peptides, or DNA as delivery vehicles, current clinical trials reflect additional platforms such as mRNA, viral vector, and other platforms (reviewed in [15, 64]. It remains ...
Areas covered : In this review, we discuss the clinical application of personalized neoantigen targeted vaccine strategy in GBM immunotherapy. While discussing this strategy, we brief about the current challenges faced in GBM treatment by the novel immunotherapeutics. Expert opinion : To date, very ...
3. A Study of a personalized neoantigen vaccine in combination with immune checkpoint blockade for patients with metastatic colorectal cancer. Clinicaltrials.gov. Accessed January 17, 2022. https://bit.ly/3fyWp9u Recent Videos Survival Gains and Challenges: The CROSS Trial in GEJ Cancer ...
These data led to the development of an optimized vaccine exclusively targeting KRAS-derived neoantigens that is being evaluated in a subset of patients in phase 2 of the clinical study. ClinicalTrials.gov registration: NCT03953235.This is a preview of subscription content, access via your ...
(Zhao et al., 2021). Clinical trials using neoantigen vaccines have demonstrated the expected therapeutic effect with high safety and efficacy (Peng et al., 2019). With technological innovations in bioinformatic approaches and the development of sequencing technologies, neoantigen-based therapies have ...
According to the authors, there are various clinical trials assessing the potential of neoantigen-based cancer vaccines, including the NEO-PV-01 trial—an open-label, phase 1b trial of the NEO-PV-01 vaccine in combination with nivolumab in 82 patients with advanced melanoma. Throughout the st...
ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?term=neoantigen+AND+vaccine&recrs=abdef&cond=Cancer (2021). Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351 (2016). Article...
The study, which found the vaccine to be well-tolerated and to stimulate the immune system, isavailableNov. 14 in the journalGenome Medicine. The Phase I clinical trial—conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine—involved 18 patients diagnosed withtriple...
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS In preclinical studies we have defined IDH1R132H as a clonal neoan...